Press Releases

Date Title
November 4, 2021 Progenity Announces Appointment of Jill Howe to its Board of Directors
SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Jill Howe to its board of directors effective November 3, 2021. Ms. Howe was also appointed chairperson of the Audit Committee and member of the Nominating
November 3, 2021 Progenity to Report Third Quarter 2021 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), an innovative biotechnology company, today announced that it will report third quarter 2021 financial results on Wednesday, November 10, 2021 after the close of financial markets.
October 26, 2021 Progenity Reduces Outstanding Debt by $20.175 Million Through a Private Exchange of $20.175 Million of Its 7.25% Convertible Senior Notes Due 2025 for Shares of Common Stock
SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into privately negotiated agreements with certain non-affiliated holders of its existing 7.25% convertible senior notes due 2025 (the
October 19, 2021 Progenity to Participate in Crohn’s & Colitis Foundation’s Fourth Annual IBD Innovate Conference
SAN DIEGO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the fourth annual IBD Innovate Product Development for Crohn’s & Colitis virtual conference, hosted by the Crohn’s & Colitis
October 13, 2021 Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has issued four patents related to its ingestible technologies for delivery of therapeutics via the
October 6, 2021 Progenity Announces Closing of $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the closing of its previously announced registered direct offering of 13,333,334 shares of the Company's common stock, at a purchase price of $1.50 per
October 4, 2021 Progenity Announces $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive agreement with several institutional investors for the purchase and sale, in a registered direct offering priced
September 21, 2021 Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference
SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11 th  annual Partnership Opportunities in Drug Delivery (PODD) Conference, October 28-29, 2021 in Boston.
September 14, 2021 Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,112,403 for assessment of preeclampsia using assays for free and dissociated
September 3, 2021 Progenity to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that the company will participate in two upcoming virtual investor conferences: A pre-recorded presentation at H.C. Wainwright’s 23rd Annual Global Investment
Displaying 11 - 20 of 103